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ABSTRACT

Microbial strains are provided, as are methods of making
and using Such microbial strains.
15 Claims, 6 Drawing Sheets
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2
the nucleic acid molecule is endogenous to the microorgan

MICROBAL STRANS AND METHODS OF
MAKING AND USING

ism. In some embodiments, the nucleic acid molecule is

exogenous to the microorganism and is expressed via a
CROSS REFERENCE TO RELATED
APPLICATIONS

COnStruct.

In yet another aspect, a mutant HodrB polypeptide is
provided. In some embodiments, the mutation includes a
substitution at position 249 relative to SEQ ID NO:3. In

This application claims benefit under 35 U.S.C. S 119(e) to
U.S. Application No. 61/980,656, filed on Apr. 17, 2014.
FEDERALLY SPONSORED RESEARCH OR
DEVELOPMENT

This invention was made with government Support under
RR017675 awarded by the National Institutes of Health. The
government has certain rights in the invention.

Some embodiments, the mutation includes a Substitution of

the methionine at position 249 relative to SEQID NO:3. In
10

15

TECHNICAL FIELD

This disclosure generally relates to microbial strains and
methods of making and using.
BACKGROUND

Methane is an increasingly important global energy
Source, both as the primary component of natural gas and as
a biologically produced fuel. Currently, Sweden uses 100%
renewable methane (biogas) in place of compressed natural
gas (CNG) for transportation fuel, and several European
countries are implementing policies to increase their pro
portion of biogas transportation fuel. In addition, methane is
a valuable chemical for conversion into other higher-order
carbon compounds (e.g., methanol, formate, alkanes, ter
penes). More than 50% of the world's methane is produced
biologically by anaerobic archaea called methanogens, but
one significant limitation with industrial scale biological
methane production from any type of feedstock is that the
rate is relatively slow.
Methanosarcina acetivorans is one of a unique group of
organisms capable of producing methane from both acetate
and methylated compounds, which are common anaerobic
fermentation end products. A genetically engineered M.

Some embodiments, the Substitution is a conservative Sub

stitution. In some embodiments, the mutant HarB polypep
tide has the sequence shown in SEQ ID NO:6.
In still another aspect, a microorganism that includes a
mutant HodrB polypeptide is provided. Such a microorgan
ism can be a methanogen. In some embodiments, the micro
organism is Methanosarcina acetivorans. In some embodi
ments, the nucleic acid encoding the polypeptide is
endogenous to the microorganism. In some embodiments,
the nucleic acid encoding the polypeptide is exogenous to
the microorganism and is expressed via a construct.
In another aspect, a method of producing methane is
provided. Such a method typically includes culturing a
microorganism as described herein under appropriate con
ditions.

25

In still another aspect, a method of biogas production is
provided. Such a method typically includes culturing a
microorganism as described herein under appropriate con
ditions.

Unless otherwise defined, all technical and scientific

35

terms used herein have the same meaning as commonly
understood by one of ordinary skill in the art to which the
methods and compositions of matter belong. Although meth
ods and materials similar or equivalent to those described
herein can be used in the practice or testing of the methods
and compositions of matter, Suitable methods and materials

40

examples are illustrative only and not intended to be limit
ing. All publications, patent applications, patents, and other
references mentioned herein are incorporated by reference in
their entirety.

30

are described below. In addition, the materials, methods, and

DESCRIPTION OF DRAWINGS

acetivorans strain is described herein that exhibits an

increased rate of methane production on methanol and on
acetate. Such genetically engineered microorganisms will be
an essential tool in the ability to use methanogens as an
inexpensive source of methane fuel derived from renewable

45

biomass.
SUMMARY
50

The disclosure provides microbial strains and methods of
making and using Such microbial strains.
In one aspect, a HarABC nucleic acid molecule including
a mutation is provided. In some embodiments, the non
mutant HarABC sequence is shown in SEQ ID NO:1. In
Some embodiments, the mutation is selected from the group
consisting of a point mutation, an insertion, a deletion, and

55

a substitution. In some embodiments, the mutant HodrABC

sequence is shown in SEQID NO:5. In some embodiments,
the nucleic acid encodes a polypeptide having an amino acid
sequence shown in SEQ ID NO:6. In some embodiments,
the mutation is at position 249 relative to SEQID NO:6. In

60

some embodiments, the mutation is a M249V substitution.

In another aspect, a microorganism including Such a
nucleic acid molecule is provided. Such a microorganism
can be a methanogen. In one embodiments, the microorgan
ism is Methanosarcina acetivorans. In some embodiments,

65

FIG. 1 shows the method of construction of plasmid pC1
and strain verification. Panel A shows the map of plasmid
pC1 containing the M. acetivorans hdraBC operon under
control of the P(tet) promoter. Panel B shows an agarose gel
indicating PCR identification of each strain. Asterisks
denote the location of point mutations in the hdraBC
operon.

FIG. 2 shows the genomic organization of each strain,
including the hadr A1C1 B1 locus in the parent strain and the
AhdraBC mutant strain before and after integration of
plasmid pC1. Blue arrows show primer binding sites.
Asterisks denote the location of point mutations in the
hdraBC operon.
FIG. 3 are graphs showing the growth curves of Strains
grown in 96-well plates on methanol--acetate medium (panel
A), and in sealed vessels on methanol medium (panel B).
Parental strain (black circles), AhdraBC mutant (gray tri
angles), plasmid pC1 integrated in the AhdraBC deletion
mutant (AhdraBC att::hdraBC, blue diamonds), plasmid
pC1 integrated into the parent strain (atthdraBC, red
squares). Growth data was collected from triplicate biologi
cal replicates.
FIG. 4 are graphs showing the phenotypes of parent and
hdraBC mutant strains. Rates of methane production by cell

US 9,598,678 B2
3
Suspensions were measured from cells grown on methanol
(panel A) and acetate (panel B). Methane production was
measured in triplicate biological and triplicate technical
replicates. Asterisks indicate p-0.0001. Panel C shows het
erodisulfide reductase activity in methanol-grown cell
extracts. Assays were performed in triplicate. Error bars

4
carbon feedstocks. The microbial strains described herein

5

denote the standard deviation.

FIG. 5 shows the correlative relationships between
HdrABC expression level and methane rate, growth rate,
and total biomass synthesis. Panel A shows that the rate of
methane production is directly dependent on the amount of

10

HdrABC enzyme activity in the cell (R* correlation coeffi
between growth rate and methane production rate (R cor

Methanobacteriales, Methanomicrobiales, Methanococca

cient of 1.00). Panel B shows the second-order relationship
relation coefficient of 0.981). Panel C shows the second
order relationship between growth rate and HarABC

les, and Methanopyrales). See, for example, Thauer, 1998,
15

coefficient of 0.959). Error bars denote the standard devia

tion.

25

metabolic efficiency (R-0.961). Error bars denote the stan

dard deviation.
DETAILED DESCRIPTION

A microbial strain is described herein, designated NB105,
which produces methane at a significantly faster rate than
the wild type strain (FIG. 1). The NB105 strain described
herein also grows faster than the parent strain under certain
conditions. This microbial strain represents a transformative

30

35

contribution to the field of renewable methane and the

production of biogas.
Attempts have been made for about thirty years to
increase biogas yield but, to date, no method has been
commercially Successful. One problem is that the strains
used in commercial-scale production facilities are not
genetically tractable and the strains that have proven to be
genetically tractable are, in other ways, not suitable for
commercial scale production digesters. In addition, there are
only a few laboratories around the world that have been able
to genetically manipulate the anaerobic microbes involved.
Simply by way of example, efficient genetic modification of
strict anaerobic microbes requires specialized microbiology,
genetics, as well as custom-built equipment. In addition,
genetic modification of Methanosarcinales and Methanococ
cus methanogens must be performed in high osmolarity
medium (e.g., containing 0.4 M Sodium chloride), which is
not routine. Further, the lack of commercially available
co-enzymes and co-factors for anaerobes (such as co-en
Zyme B, co-enzyme F430, co-enzyme F420), means that the
cofactors must be extracted or synthesized. Therefore,
genetic investigation of biosynthetic pathways in anaerobes
is prohibitively difficult. Methanogens also are not suscep
tible to most traditional antibiotics, so the paucity of select
able and counterselectable markers for genetically manipu
lating methanogens adds another layer of complexity that
serves as a significant barrier to working with methanogens.

40

45

In methanogens that lack cytochromes, the heterodisulfide
reductase-like proteins (HDR) enzyme is soluble and com
posed of three subunits, HdrABC, whereas methanogens
that have cytochromes have two classes of HDR enzyme:
HdrABC, as in non-cytochrome containing methanogens, as
well as membrane-associated HDR formed by two subunits,
HdrDE. In the HarABC enzyme, the HarA subunit is an
iron-sulfur flavoprotein, the HarC subunit is a small iron
sulfur protein, and the HarB subunit contains two GGC
domains and harbors a special 4Fe4S catalytic site.
The soluble HarABC enzyme forms a complex with the
soluble MvhaDGHase, which then catalyzes heterodisulfide
reduction in the presence of H2. This exergonic reaction is
proposed to be coupled to the endergonic reduction of
ferredoxin (Fd) by flavin-based electron bifurcation involv
ing HarA (see, for example, Thauer et al., 2008, Nat. Rev.
Microbiol. 6:579-91). Flavin-based electron bifurcation
(FBEB) is an important mechanism for the energy metabo
lism of anaerobes. A family of NADH dehydrogenases, the
flavin oxidoreductase (Flx ABCD, previously called Flox
ABCD), coupled with heterodisulfide reductase (HdrABC),
both of which are widespread in anaerobic bacteria, perform
FBEB in Sulphate-reducing organisms.
HdrABC Nucleic Acids and Polypeptides
The nucleic acid sequence of a reference wild type
HdrABC operon is shown in SEQID NO:1 with each of the
encoded reference polypeptides shown in SEQ ID NO:2
(HdrA), SEQ ID NO:3 (HdrB), and SEQID NO:4 (HdrC)).
As used herein, nucleic acids can include DNA and RNA,
and includes nucleic acids that contain one or more nucleo

50

55

tide analogs or backbone modifications. A nucleic acid can
be single stranded or double stranded, which usually
depends upon its intended use.
Also provided are nucleic acids and polypeptides that
differ from such reference sequences (e.g., SEQ ID NO:1
and SEQ ID NOS: 2, 3 and 4, respectively). Nucleic acids
and polypeptides that differ in sequence from SEQID NO:1
and SEQID NOS: 2, 3, or 4, can have at least 50% sequence
identity (e.g., at least 55%, 60%. 65%, 70%, 75%, 80%,
81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%,
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%

60

The microbial strains described herein have been

designed using a specialized knowledge of the biology,
genetics, and biochemistry of microbial fermentation,
anaerobic digestion, and biogas production from renewable

Microbiol., 144:2377-406; and Wolfe, 1996, ASM News,
62:529-34.

enzyme activity (R correlation coefficient of 0.990). Panel
D shows HarABC enzyme activity has a strong negative
correlation with total biomass synthesis (R correlation

FIG. 6 shows the mechanism of methane rate improve
ment in the hdraBC overexpressing strain. Panel A shows
the metabolic efficiency of each strain. Values are normal
ized to the AhdraBC mutant strain. Panel B shows a strong
negative correlation between HarABC enzyme activity and

demonstrate that it is, in fact, possible to genetically engi
neer an increase in the rate and yield of biogas production in
methanogens.
The HarABC Operon
Methanogenic archaea have been divided into two cat
egories: those that contain cytochromes and can use metha
nol, methyl amines, acetate, carbon monoxide, and/or CO
plus H2 as methanogenic Substrates (i.e., those belonging to
the order Methanosarcinales), and those that are devoid of
cytochromes and can use CO plus H2 and/or formate only
to fuel anaerobic growth (i.e., those belonging to the orders

65

sequence identity) to SEQ ID NO:1 and SEQID NOs: 2, 3,
or 4, respectively. Simply by way of example, sequences that
differ from SEQ ID NO:1 and SEQ ID NO:3 are shown in
SEQ ID NO:5 and SEQ ID NO:6, respectively.
In calculating percent sequence identity, two sequences
are aligned and the number of identical matches of nucleo
tides or amino acid residues between the two sequences is
determined. The number of identical matches is divided by
the length of the aligned region (i.e., the number of aligned
nucleotides or amino acid residues) and multiplied by 100 to

US 9,598,678 B2
5
arrive at a percent sequence identity value. It will be
appreciated that the length of the aligned region can be a
portion of one or both sequences up to the full-length size of
the shortest sequence. It also will be appreciated that a single
sequence can align with more than one other sequence and
hence, can have different percent sequence identity values
over each aligned region.
The alignment of two or more sequences to determine
percent sequence identity can be performed using the com
puter program ClustalW and default parameters, which
allows alignments of nucleic acid or polypeptide sequences
to be carried out across their entire length (global align
ment). Chenna et al., 2003, Nucleic Acids Res., 31 (13):

10

3497-500. ClustalW calculates the best match between a

query and one or more subject sequences, and aligns them

15

so that identities, similarities and differences can be deter

mined. Gaps of one or more residues can be inserted into a
query sequence, a Subject sequence, or both, to maximize
sequence alignments. For fast pairwise alignment of nucleic
acid sequences, the default parameters can be used (i.e.,
word size: 2; window size: 4; scoring method: percentage;
number of top diagonals: 4; and gap penalty: 5); for an
alignment of multiple nucleic acid sequences, the following
parameters can be used: gap opening penalty: 10.0; gap
extension penalty: 5.0, and weight transitions: yes. For fast
pairwise alignment of polypeptide sequences, the following
parameters can be used: word size: 1; window size: 5;
scoring method: percentage; number oftop diagonals: 5; and
gap penalty: 3. For multiple alignment of polypeptide
sequences, the following parameters can be used: weight
matrix: blosum, gap opening penalty: 10.0; gap extension
penalty: 0.05; hydrophilic gaps: on; hydrophilic residues:
Gly, Pro, Ser, ASn, Asp, Gln, Glu, Arg, and Lys; and
residue-specific gap penalties: on. ClustalW can be run, for
example, at the Baylor College of Medicine Search
Launcher website or at the European Bioinformatics Insti

25

As used herein, an "isolated nucleic acid molecule is a
30

35

tute website on the World Wide Web.

Changes can be introduced into a nucleic acid molecule,
thereby leading to changes in the amino acid sequence of the
encoded polypeptide. For example, changes can be intro
duced into nucleic acid coding sequences using mutagenesis
(e.g., site-directed mutagenesis, PCR-mediated mutagen
esis) or by chemically synthesizing a nucleic acid molecule
having Such changes. Such nucleic acid changes can lead to
conservative and/or non-conservative amino acid substitu
tions at one or more amino acid residues. A "conservative
amino acid substitution' is one in which one amino acid

residue is replaced with a different amino acid residue
having a similar side chain (see, for example, Dayhoff et al.
(1978, in Atlas of Protein Sequence and Structure, 5(Suppl.
3):345-352), which provides frequency tables for amino acid
Substitutions), and a non-conservative Substitution is one in
which an amino acid residue is replaced with an amino acid

40

45

50

55

an HodrABC operon that contains at least one mutation. A
mutation can be located within any portion of the HarABC
nucleic acid operon Such that any of the encoded polypep
tides, HdrA, HdrB or HodrC, contain a mutation. As used

herein, a mutation within HarABC typically is a mutation
that results in, for example, a conservative or non-conser
vative substitution; a mutation within HarABC typically is
not a null mutation (i.e., a mutation that results in the lack
of expression or in a non-functional protein). A mutation in
a HarABC sequence as described herein can be contained
within an endogenous HodrABC sequence or a mutation in a
HdrABC sequence as described herein can be contained

nucleic acid molecule that is free of sequences that naturally
flank one or both ends of the nucleic acid in the genome of
the organism from which the isolated nucleic acid molecule
is derived (e.g., a cDNA or genomic DNA fragment pro
duced by PCR or restriction endonuclease digestion). Such
an isolated nucleic acid molecule is generally introduced
into a vector (e.g., a cloning vector, or an expression vector)
for convenience of manipulation or to generate a fusion
nucleic acid molecule, discussed in more detail below. In
addition, an isolated nucleic acid molecule can include an

residue that does not have a similar side chain.

As used herein, a mutant HodrABC nucleic acid refers to

6
within an exogenous sequence (e.g., expressed/overex
pressed on a construct). In addition, a mutant HarABC
sequence can be autologous (i.e., from the same species) or
heterologous (i.e., from a different species) to a microor
ganism.
A representative HarABC nucleic acid containing a muta
tion is shown in SEQ ID NO:5, and a representative HarB
protein that contains a mutation is shown in SEQID NO:6.
In some embodiments, the mutation can at position 249
relative to the HarB sequence shown in SEQ ID NO:3 and,
for the reference sequence shown in SEQ ID NO:3, the
mutation corresponds to a methionine to valine Substitution
(i.e., M249V). As indicated herein, however, other substi
tutions at that residue (e.g., residue 249 relative to SEQ ID
NO:3) also would be expected to impart the same or similar
phenotype (e.g., M249X). In some instances, the methionine
residue at position 249 can be replaced, for example, with an
alanine (M249A), an isoleucine (M249I), a leucine
(M249L), or a glycine (M249G) residue. Alternatively, the
methionine residue at position 249 can be replaced, for
example, with a phenylalanine (M249F), a proline (M249P),
a tryrosine (M249Y), or a tryptophan (M249W). It would be
understood by a skilled artisan that the methionine residue at
position 249 can be replaced with any of the other remaining
amino acids, provided Such Substitutions do not result in a
protein that completely lacks function and provided Such
Substitutions impart the desired phenotype.

60
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engineered nucleic acid molecule Such as a recombinant or
a synthetic nucleic acid molecule.
As used herein, a “purified’ polypeptide is a polypeptide
that has been separated or purified from cellular components
that naturally accompany it. Typically, the polypeptide is
considered “purified when it is at least 70% (e.g., at least
75%, 80%, 85%, 90%. 95%, or 99%) by dry weight, free
from the polypeptides and naturally occurring molecules
with which it is naturally associated. Since a polypeptide
that is chemically synthesized is, by nature, separated from
the components that naturally accompany it, a synthetic
polypeptide is “purified.”
Nucleic acids can be isolated using techniques routine in
the art. For example, nucleic acids can be isolated using any
method including, without limitation, recombinant nucleic
acid technology, and/or the polymerase chain reaction
(PCR). General PCR techniques are described, for example
in PCR Primer: A Laboratory Manual, Dieffenbach & Dvek
sler, Eds. Cold Spring Harbor Laboratory Press, 1995.
Recombinant nucleic acid techniques include, for example,
restriction enzyme digestion and ligation, which can be used
to isolate a nucleic acid. Isolated nucleic acids also can be

chemically synthesized, either as a single nucleic acid mol
ecule or as a series of oligonucleotides.
Polypeptides can be purified from natural Sources (e.g., a
biological sample) by known methods such as DEAE ion
exchange, gel filtration, and hydroxyapatite chromatogra
phy. A polypeptide also can be purified, for example, by
expressing a nucleic acid in an expression vector. In addi

US 9,598,678 B2
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tion, a purified polypeptide can be obtained by chemical
synthesis. The extent of purity of a polypeptide can be
measured using any appropriate method, e.g., column chro
matography, polyacrylamide gel electrophoresis, or HPLC
analysis.
A construct, also referred to as a vector, containing a
nucleic acid (e.g., a nucleic acid that encodes a polypeptide)
also is provided. Constructs, including expression vectors,
are commercially available or can be produced by recom
binant DNA techniques routine in the art. A construct
containing a nucleic acid can have expression elements
operably linked to such a nucleic acid, and further can
include sequences such as those encoding a selectable
marker (e.g., an antibiotic resistance gene). A construct
containing a nucleic acid can encode a chimeric or fusion
polypeptide (i.e., a polypeptide operatively linked to a
heterologous polypeptide, which can be at either the N-ter
minus or C-terminus of the polypeptide). Representative
heterologous polypeptides are those that can be used in
purification of the encoded polypeptide (e.g., 6x His tag,
glutathione S-transferase (GST))
Expression elements include nucleic acid sequences that
direct and regulate expression of nucleic acid coding
sequences. One example of an expression element is a
promoter sequence. Expression elements also can include
introns, enhancer sequences, response elements, or inducible
elements that modulate expression of a nucleic acid. Expres
sion elements can be of bacterial, yeast, insect, mammalian,
or viral origin, and vectors can contain a combination of
elements from different origins. As used herein, operably
linked means that a promoter or other expression element(s)
are positioned in a construct relative to a nucleic acid in such
a way as to direct or regulate expression of the nucleic acid
(e.g., in-frame).
A skilled artisan would appreciate that gene expression in
methanogens typically requires at least one methanogen
specific expression element, since the transcriptional
machinery in methanogens is a hybrid between bacterial and
eukaryotic transcription systems. For example, for expres
sion of genes in methanogens, the promoter is usually
derived from another methanogen gene to ensure that the
methanogen RNA polymerase and other accessory proteins
needed for transcription will recognize the promoter
sequences and initiate transcription. However, other expres
sion elements such as protein transcriptional regulators
and/or riboswitches from phylogenetically distant relatives
(e.g., eukaryotic or bacterial) can be adapted for use in
methanogen cells. See, for example, Buan et al., 2011,
Methods Enzymol., 494:23-42; Demolli et al., 2014, Archea,
do: 10.1155/2014/72561O.
Constructs as described herein can be introduced into a

8
tory Manual, 1995, Dieffenbach & Dveksler, Eds. Cold
Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.:
and U.S. Pat. Nos. 4,683, 195; 4,683.202; 4,800,159; and

4.965, 188) with an appropriate pair of oligonucleotides
(e.g., primers). A number of modifications to the original
PCR have been developed and can be used to detect a
nucleic acid.
10
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of Sambrook et al.
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Other suitable host cells are known to those skilled in the art.
60

both in vivo and in vitro, are well known to those skilled in

the art and include, without limitation, electroporation,
calcium phosphate precipitation, polyethylene glycol (PEG)
transformation, heat shock, lipofection, microinjection, and
viral-mediated nucleic acid transfer.

Nucleic acids can be detected using any number of
amplification techniques (see, e.g., PCR Primer: A Labora

In addition, interpreting the amount of hybridization can
be affected, for example, by the specific activity of the
labeled oligonucleotide probe, by the number of probe
binding sites on the template nucleic acid to which the probe
has hybridized, and by the amount of exposure of an
autoradiograph or other detection medium. It will be readily
appreciated by those of ordinary skill in the art that although
any number of hybridization and washing conditions can be
used to examine hybridization of a probe nucleic acid
molecule to immobilized target nucleic acids, it is more
important to examine hybridization of a probe to target
nucleic acids under identical hybridization, washing, and
exposure conditions. Preferably, the target nucleic acids are
on the same membrane.

cell into which the nucleic acid is introduced and also

Many methods for introducing nucleic acids into host cells,

The conditions under which membranes containing
nucleic acids are prehybridized and hybridized, as well as
the conditions under which membranes containing nucleic
acids are washed to remove excess and non-specifically
bound probe, can play a significant role in the stringency of
the hybridization. Such hybridizations and washes can be
performed, where appropriate, under moderate or high Strin
gency conditions. For example, washing conditions can be
made more stringent by decreasing the salt concentration in
the wash solutions and/or by increasing the temperature at
which the washes are performed. Simply by way of
example, high Stringency conditions typically include a
wash of the membranes in 0.2XSSC at 65° C.

host cell. As used herein, “host cell refers to the particular
includes the progeny of Such a cell that carry the construct.
A host cell can be any prokaryotic or eukaryotic cell. For
example, nucleic acids can be expressed in bacterial cells
Such as E. coli, or in insect cells, yeast or mammalian cells
(such as Chinese hamster ovary cells (CHO) or COS cells).

Nucleic acids also can be detected using hybridization.
Hybridization between nucleic acids is discussed in detail in
Sambrook et al. (1989, Molecular Cloning: A Laboratory
Manual, 2nd Ed., Cold Spring Harbor Laboratory Press,
Cold Spring Harbor, N.Y.; Sections 7.37-7.57, 9.47-9.57,
11.7-11.8, and 11.45-11.57). Sambrook et al. discloses suit
able Southern blot conditions for oligonucleotide probes less
than about 100 nucleotides (Sections 11.45-11.46). The Tm
between a sequence that is less than 100 nucleotides in
length and a second sequence can be calculated using the
formula provided in Section 11.46. Sambrook et al. addi
tionally discloses Southern blot conditions for oligonucle
otide probes greater than about 100 nucleotides (see Sec
tions 9.47-9.54). The Tm between a sequence greater than
100 nucleotides in length and a second sequence can be
calculated using the formula provided in Sections 9.50-9.51

65

A nucleic acid molecule is deemed to hybridize to a
nucleic acid but not to another nucleic acid if hybridization
to a nucleic acid is at least 5-fold (e.g., at least 6-fold, 7-fold,
8-fold, 9-fold, 10-fold, 20-fold, 50-fold, or 100-fold) greater
than hybridization to another nucleic acid. The amount of
hybridization can be quantitated directly on a membrane or
from an autoradiograph using, for example, a Phosphorm
ager or a Densitometer (Molecular Dynamics, Sunnyvale,
Calif.).
Polypeptides can be detected using antibodies. Tech
niques for detecting polypeptides using antibodies include
enzyme linked immunosorbent assays (ELISAs), Western
blots, immunoprecipitations and immunofluorescence. An
antibody can be polyclonal or monoclonal. An antibody
having specific binding affinity for a polypeptide can be
generated using methods well known in the art. The anti
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plant downtime and labor costs. Thus, the methods
described herein can significantly reduce the costs involved
with the production of biogas.

body can be attached to a solid Support such as a microtiter
plate using methods known in the art. In the presence of a
polypeptide, an antibody-polypeptide complex is formed.
Detection (e.g., of an amplification product, a hybridiza
tion complex, or a polypeptide) is usually accomplished
using detectable labels. The term “label' is intended to
encompass the use of direct labels as well as indirect labels.
Detectable labels include enzymes, prosthetic groups, fluo
rescent materials, luminescent materials, bioluminescent
materials, and radioactive materials.

In some embodiments, a live culture of the microbial

10

Methods of Making Biogas

The microbial strains described herein can be used to

make biogas (e.g., methane). As demonstrated herein, cul
turing such microbial strains under the appropriate condi
tions results in the production of biogas (e.g., methane). It
would be appreciated by a skilled artisan that the “appro
priate conditions’ under which a microorganism is cultured
will depend upon the particular microorganism used, and
can include, without limitation, a particular culture media,
the temperature at which the culture is maintained, the
requirement for the presence or absence of oxygen, a par

15

strain described herein to further increase biogas production
example, yield, increased growth rate, the ability to use
novel Substrates, or resistance to oxidative stress. The micro

bial strain described herein also can be a part of a microbial
consortia (e.g., a microbial community that has evolved
together) to be able to efficiently convert various renewable

The microbial strains described herein can be used to

feedstocks to methane and/or additional fermentation co
25

while one of the mutant strains described herein, NB105

(att::hdraBC), produced methane at a rate of 282+31.8
nmoles min-1 mg-1; this represents a 28.9% increase in rate.
As used herein, an “increase' in the amount of biogas that
is produced or an increase in the rate at which a biogas is
produced refers to an increase (e.g., a statistically significant
increase) by at least about 5% up to about 95% (e.g., about
5% to about 10%, about 5% to about 20%, about 5% to about
50%, about 5% to about 75%, about 10% to about 25%,
about 10% to about 50%, about 10% to about 90%, about
20% to about 40%, about 20% to about 60%, about 20% to
about 80%, about 25% to about 75%, about 35% to about
55%, about 35% to about 50%, about 50% to about 75%,
about 50% to about 85%, about 50% to about 95%, and

about 75% to about 95%) relative to a corresponding
microbe lacking the mutation. It would be appreciated by a
person of ordinary skill in the art that, to compare a mutant
microbial Strain with a corresponding microbial strain lack
ing the mutation, culture conditions used to grow each
microbial strain should be as similar as possible, referred to
herein as “corresponding conditions'. As used herein, sta
tistical significance refers to a p-value of less than 0.05, e.g.,
a p-value of less than 0.025 or a p-value of less than 0.01,
using an appropriate measure of Statistical significance, e.g.,
a one-tailed two sample t-test.
Current practices for producing renewable methane use
innocula of microbes, usually obtained from animal manure
(e.g., Swine or cattle manure) to digest organic carbon under
anaerobic conditions. As a result, anaerobic digesters fre
quently fail and must be shut down, cleaned, and restarted on
a regular basis. These failures represent a large cost in time,
effort, wages, and lost revenue. The methods described
herein can be used to increase biogas yield, require less
feedstock, increase the overall rate of feedstock decompo
sition, reduce labor, and help stabilize production because
operators would not solely rely on populations of wild
microbes as the feedstock. In addition, the methods

described herein require less feedstock than current meth
ods, and anaerobic digesters would fail less often, saving

environment.
Additional mutations can be introduced into the microbial

or to increase other features of the Strain Such as, for

ticular carbon Source, and/or one or more co-factors.

make biogas (e.g., methane) at an increased rate relative to
the parent strain and/or an increased amount relative to the
parent strain. For example, as described herein, under cor
responding culture conditions, the parent strain, NB34.
produced methane at a rate of 219+18.9 nmoles min-1 mg-1.

strain described herein is added (e.g., inoculated) to a
digester at regular intervals. In some embodiments, the
microbial strains described herein can be provided in, for
example, a lyophilized or dehydrated form. One of the
advantages of the microbial strain described herein is that,
because it is anaerobic, in the absence of very particular
growth conditions, microbes from the microbial strain
described herein will not survive. This feature significantly
reduces the possibility of unintentional release into the

30

products.
Biogas made by the methods described herein can be
used, without limitation, for renewable energy, compressed
biogas/natural gas for transportation, microbial fermentation
or respiration (bioorganic catalysis), or any other technology
that uses methane or biogas including (in)organic catalytic
synthesis technologies.
Further, a mutant HarABC nucleic acid sequence as
described herein can be introduced into other microbial

35

40

45

50

organisms having industrial or biotechnological utility in
order to alter those strains. HarABC homologs and
orthologs are found in the genomes of non-methanogenic
archaea and bacteria, Such as members of the genus Metal
losphaera, Archaeoglobus, Sulfate-reducing bacteria (in
cluding, but not restricted to, Desulfovibrio, Desulfotomacu
lum), Moorella, Aquifex, Sulfolobus, Carboxydothermus,
Pelotomaculum, Chlorflexi (including, but not restricted to,
Chloroflexus, Chlorobium), syntrophs (including, but not
restricted to, Syntrophomonas), and metal-reducing or
metal-oxidizing microbes such as Geobacter, and could be
mutated (or a mutant sequence overexpressed) in any of
Such species The above-mentioned mutant species can be
used for bioremediation or metal bioleaching, aerobic or
anaerobic fermentations (including gas fermentation), and
production of biofuel cells, and would exhibit increased rate
and yield of fermentation and/or respiration.
In accordance with the present invention, there may be
employed conventional molecular biology, microbiology,
biochemical, and recombinant DNA techniques within the
skill of the art. Such techniques are explained fully in the
literature. The invention will be further described in the
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following examples, which do not limit the scope of the
methods and compositions of matter described in the claims.
EXAMPLES

60

Example 1
Materials and Methods

65

Cell growth curves were determined by monitoring the
optical density (OD) of the cells in culture over time. The
OD of the cells was determined using two methods as
indicated: (1) using growth in Balch tubes and obtaining the
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OD manually every 4 hours for 3-7 days using a Spectronic
20 D+ spectrophotomter (“BT+Spec 20), where; or (2)
using an anaerobic plate reader and obtaining the OD
automatically every 2 hours. For biomass measurements of
each strain, ten cultures (10 ml) were grown to stationary
phase on HS medium containing 125 mM MeOH. Methane
in the headspace was measured as described below, and cells
were collected on pre-weighed 0.2 um nylon filters by
vacuum. Filters were dried at 95°C. and weighed daily until
weights stabilized and remained consistent for three days.

5

10

Uninoculated medium was used as a blank.

The amount and rate of methane production was deter
mined using gas chromatography (GC). For methane end
point assays, 10 ml cultures were grown in 125 mM metha
nol HS medium to stationary phase, and 100 ul headspace
samples were transferred to empty, crimped 2 ml serum vials
using a gastight Hamilton Syringe. For cell Suspension
assays, cells were grown with appropriate carbon source to
an OD(600) of between 0.3 and 0.5 (exponential growth)
and put on ice. Under strict anaerobic conditions, cells from
10 ml culture were harvested, pelleted by centrifugation, and

15

washed twice in HS media without a carbon source. Cells

were resuspended in 0.5 ml HS media with 50 uM mupirocin
to halt protein synthesis, then aliquoted into 2 ml serum vials
containing HS+125 mM MeOH or 120 mM acetate in
replicates of 5. Serum vials were sealed with aluminum
crimps and warmed for 5 minutes at 35°C. to start the assay.
Methane in the headspace was measured via flame ioniza
tion on an Agilent 7890 Gas Chromatograph with a GS
CarbonPLOT column at 145° C. using an auto injector.
The amount of HarABC enzyme activity was measured
by biochemical assay. Coenzyme M was purchased from
Sigma-Aldrich (St. Louis, Mo.). Coenzyme B and CoM-SS-CoB was synthesized in-house (Welte and Deppenmeier,
2014, Biochim. Biophys. Acta., 1837: 1130-47). Cells were
grown to early stationary phase (OD(600) of 1.0) in HS
supplemented with 125 mM MeCH. Under strict anaerobic
conditions, 30 ml of cell cultures were harvested, pelleted by
centrifugation, and washed twice with 10 ml 0.1 M NaPO,
0.4 M NaCl (pH 8.0). Cells were lysed osmotically by
addition of 3 ml 0.1 M NaPO (pH 8.0) without NaCl.
Protease inhibitor cocktail (Thermo Pierce) was added, and
the lysate was centrifuged at 22,000xg for one hour to pellet

12
oNB72-oNB81 introduced five point mutations to remove
five Ndel restriction sites from the hdraCB operon. The
resulting fused PCR product contained BamHI restriction
sites at the 5' and 3' ends, as well as an Ndel site preceding
the start codon of the hdra gene. The PCR product was
ligated into plasmid pNB708, creating pNB709, and verified
by restriction digest and sequencing. The mutated hdraCB
operon was amplified from pNB709 using oligos onB68 and
oNB69, and ligated into plK027A at the Ndel and BamHI
restriction sites to create plasmid pC1 (Table 1). The
hdraBC operon is under control of the PmcrB(tetO1) (aka
Ptet) promoter. The Ptet promoter is constitutive when
transformed into strains lacking the tetR repressor gene, but
can be controlled by addition of tetracycline in strains that
express TetR repressor. M. acetivorans was transformed
with pC1 as previously described (Buan and Metcalf, 2010,
Mol. Microbiol. 75:843-53). Transformants were verified
via PCR screen for wild type harABC, the AhdraBC operon
deletion, and Ptet hdraBC (in pC1) using primers listed in
Table 2. Various PCR techniques were employed to create
methanophenazine mutant strains (listed in Table 1), includ
ing overlap extension and site-directed mutagenesis.
For all PCR reactions, Phusion Flash PCR Master Mix

25
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was used as a source of proofreading DNA polymerase
(Thermo Scientific). DNA purification was carried out using
Wizard kits from Promega (Madison, Wis.). DNA fragments
were joined using T4 DNA Ligase (New England Biolabs)
or GeneArt kits (Invitrogen). Restriction enzymes (AScI.
BamHI, Ndel. Ncol, EcoRI, SphI, Xbal) were purchased
from New England Biolabs (Ipswich, Mass.). All plasmids
were sequenced by Eurofins Operon MWG (Huntsville,
Ala.).
After purification from E. coli, the plasmids were trans
fected into M. acetivorans using liposome-mediated trans
fection (using the DOTAP liposome transfection reagent
from Roche), and the operon was recombined into the
genome. Colonies then were selected for puromycin resis
tance (from the puromycin acetyltransferase cassette
included on the plC1 vector). Certain of the strains and their
genotype are provided in Table 1.
TABLE 1.

cell debris and membranes. The concentration of soluble

cytoplasmic protein in the resulting extract was measured
via Bradford assay against a 2 mg BSA standard (Thermo
Pierce). Har assays (Welte and Deppenmeier, 2014, Supra)
were modified for a 96-well plate format. Briefly, reactions
were prepared with 170 ul 0.1 M NaPO (pH 8.0), 28 ul
extract and 2 ul methyl viologen. The reaction was began
with the addition of 30 ul CoM-CoB heterodisulfide, and the
increase in oxidized methyl viologen was followed at 578
nm in a Tecan Sunrise plate reader at 35° C.
Example 2
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Strains and Genotypes
E. coli strains
NB

# Genotype

Purpose

3 F" proA+B+ lacla A(lacz)M15

5C. Flacl2.

New

ZZf::Tn10 (TetR)ffhuA2A(argF-

Replication of

England

lacz)U169 phoA glnV44

pNEB193

Biolabs

d80A(lacZ)M15 gyra96 recA1

derived plasmids.

endA1 thi-1 hsdR17
55

General Description of Strain Construction

10 F- mcra A(mirr-hsdRMS-mcrBC) DH10B att::pAMG27.
p80laczAM15 AlacX74 recA1
Replication of oriV
arad139 A(ara-leu) 7697 gall J
copy-control plasmids.
galK rpsL (StrR) endA1 nupG - High copy replication
att::Prha trfA33-254D

To generate the AhdraBC strains, the hdraBC sequence
was mutated using site-directed mutagenesis and overlap
ping PCR. Primers and DNA sequences in Table 2 were
designed using Vector NTI software (Invitrogen). Genes,
oligos, and multiple cloning sites were synthesized com
mercially by IDT and Invitrogen. To overexpress hdraCB,
the operon (MA3126-3128) was amplified from the M.
acetivorans chromosome (strain NB34) using primers
oNB68, onB69, and oNB72-81 (listed in Table 2). Primers

Source

50

Guss
AM,
et al.
2008

is induced by addition
of rhamnose.

60

pNEB193 derivative plasmids
NB

#
65

Plasmid

Genotype

13 plJC ori,
bla-

Purpose

l8le

Source

E. coli cloning

pNEB193 New
England
Biolabs

US 9,598,678 B2
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TABLE 1-continued
Strains and Genotypes
adds Ncol site to pNEB193

47 plJC ori,
bla--,

Construction of the NB105 Strain
pNB708

This

The hdraBC genes (MA3126-3128; see Galagan et al.,

study

2002, Genome Res., 12:532-42; see, also, GenBank Acces

Nicol

48 plJC ori,
bla--,

M. acetivorans Ndel

pNB709

hdraBC

This

study

hdra1C1B1 operon (with
all internal Ndel sites

removed) cloned into the
10

BamHI site

pK027A derivative plasmids

and create mutations that remove internal Ndel restriction
Plasmid

NB

Purpose

# Genotype

Source
15

Integration at pC31
53 oriV, repE,
attP site
sopABC, cat,
(pC31 attB,
Pmcr (M. voltae)
pac-hpt,
PtetO1 uidA
83 PtetO1
hdraBC

plKO27A

Guss

AM,
et al.
2008

Constitutive overproduction plC1
and complementation
of HodrABC protein

This

study

in Meihanosarcina.

Tetracycline-controlled
expression of HolrABC in

25

tetR+ Methanosarcina
strains.
Methanosarcina acetivorans C2A strains
30

NB

i

Purpose

Genotype

34 Ahpt::pC31 int, attP

sion No. AE010299) were amplified from the M. acetivorans
chromosome (strain NB34, propagated from M. acetivorans
strain, WWM82, from Dr. Metcalf's Lab, University of
Illinois, Urbana-Champaign on July 2010) chromosome
using primers oNB68, onB69, onB72-81 (see Table 2). The
listed oligos simultaneously amplify the hadr ABC operon

Source

Parental strain

S86 8S

WWM82

36 AhdraCBAAhpt::cpC31 AhdraBC mutant
int, attP
Effect of constitutive
105 Ahpt::pC31 int,
overproduction

S86 8S

WWM287
This

35

study

of HoraBC. att::hdraBC

106 AhdraCB Ahpt::pC31 Complementation of
int, att::pC1
Ahdra BC by plC1.

This

study

AhdraBC att::hdraBC

40

sites (the wild-type operon contains five) and results in a
PCR product that has a BamHI restriction site after the stop
codon on the 3' end of the operon.
The mutated hdraBC operon then was cloned into the E.
coli plasmid, pNB708, at the BamHI site. pNB708 was
produced using oligos, onB60 and oNB61 (see Table 2), to
amplify plasmid, pNEB 193 (purchased from New England
Biolabs). The resulting PCR product was digested with
Dpn1 and transformed into E. coli strain, NB3 (New Eng
land Biolabs), to produce plasmid, pNB708, which has a
new Ncol site in the plasmid. The E. coli strain carrying
pNB708 was designated NB47.
The resulting plasmid, pNB709, carried in E. coli strain,
NB48, was used as a template in subsequent PCR reactions
to amplify the mutated hdraBC operon with oligos, onB68
and onB69 (see Table 2). The mutated hdraBC operon was
cloned into pK027A at the Ndel and BamHI sites to
produce plasmid pC1. p C1 contains a pC31 attP site, and,
in the presence of (pC31 recombinase, is inserted into any
DNA containing the pC31 attB site. p.JC1 also contains a
mutated hdraBC operon driven by the PtetO1 promoter,
which is transcribed constitutively in Methanosarcina spe
cies unless the parent strain expresses a TetR repressor
protein, in which case, HdrABC expression is rendered
tetracycline-inducible by TetR binding to the tetO1 operator
site on the promoter. pC1 was transformed into NB34 to
create strain NB105, in which pC1 has recombined into the
M. acetivorans (NB34) chromosome at the hpt locus. In
cell-suspension assays with methanol, strain NB105 pro
duced methane at a rate that was 35% faster than that of the

NB34 parent strain.
TABLE 2

Oligonucleotide Sequences
oNB: Purpose

Sequence (5'-3')

SEQ ID NO:

hdrABC primers
68

M. acetivorans BamHI
Ndle horABC BamHI fwc
M. acetivorans BamHI
Ndle horABC BamHI rew

GGATCCCATATGACTGACGGGCTGAACAAAGCT

7

GGATCCCCCTCTTCACTCCCGATGTAATAAAAAAGGTAGCCAGTTC

8

72
73

removes NdeI site 1. fwo
removes NdeI site 1. rew

GAGAAATTGCCTTTTTGTCCATGTGTCCGCAGTTGAACTCGTC
GACGAGTTCAACTGCGGACACATGGACAAAAAGGCAATTTCTC

9
1O

74
75

removes NdeI site
removes NdeI site

fwo

CCTTTTGTGTTCGGAACGTATGCTTTTTTGAAATAGATCCGG
CCGGATCTATTTCAAAAAAGCATACGTTCCGAACACAAAAGG

11
12

76
77

removes NdeI site
removes NdeI site

fwo

GGCATCATCTTTACATAGGGTATCATCTTATCATCTCTC
GAGAGATGATAAGATGATACCCTATGTAAAGATGATGCC

13
14

78
79

removes NdeI site
removes NdeI site

fwo

GGGTATCGTATTCGTTTACATAGGGCATCATCTTTACATATGG
CCATATGTAAAGATGATGCCCTATGTAAACGAATACGATACCC

15
16

80
81

removes NdeI site
removes NdeI site

fwo

GATATGGCAGTTCGGGCACATGTGGATCATTAGCTCCACACC
GGTGTGGAGCTAATGATCCACATGTGCCCGAACTGCCATATC

17
18

69

rew

rew

rew

rew
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TABLE 2- Continued

Oligonucleotide Sequences
oNB: Purpose

Sequence (5'-3')

122 horA: amplifies within

SEQ ID NO :

TACTGGGGTTTCTGGGAGAC

19

ATGGTCTTGCTCTCAGCGATGA

2O

AGGTGTTGGTATGAAAATCAGCAAGG

21

inside both parent and
insert hdra.

376 identify hdrABC deletion:

amplifies 5' upstream of
MA3128

377 identify hdrABC deletion:

amplifies 3" downstream
of MA3126

379 identify Ptet hdrABC insert ATCAGTGATAGAGATTTCATTGGGAATAGT

22

Example 4
Evaluation of Strains

The growth kinetics of the strains indicated above in Table
1 were used to evaluate the growth phenotypes of each strain
on methanol, methanol--acetate, or acetate Substrates, using
Method (1) described above (“BT+Spec20), and the results

25

are shown in Table 3.
TABLE 3

Culture Doubling Time for Adapted Cells (Hours
Growth Substrate
MeOH

Strain
Parent
att::hdraBC
AhdraBC
att::hdraBC
AhdraBC

hours

Std
dev

p vs
Parent

MeOH + Acetate

p vs
AhdraBC hours

Std
dev

p vs
Parent
1

8.5
8.4
9.1

O.17 1
0.11
NS
0.14 O.OO12

OOOOO
O.OOO1
OOO10

9.4
9.7
10.3

O.28
0.16
0.48

9.9

0.24 OOOOO

1

10.1

-0.2O O.OO46

NS
NS

Acetate

p vs
AhdraBC hours

Std
dev

p VS
Parent

p VS
AhdraBC

OOO46
NS
NS

44.O
47.6
S8.0

280 1
2.64
NS
3.05 O.OOO2

O.OOOO
O.OOO3
NS

1

61.8

2.94 OOOOO

1

Cells were adapted to methanol for 25 generations. Data were collected from five biological replicates (N = 5). Significance p values determined
by unpaired Student's t-test,
NS: not significant, p > 0.01.

The strains indicated above in Table 1 were used to
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TABLE 4-continued

evaluate the production of methane from methanol or acetate
using Method (1) described above (methane production and
biomass measurements), and the results are shown in Table
4.

Growth Yield and Methane Yield
Methane
50 Strain

TABLE 4

Parent
att::hdraBC
AhdraBC att::hdraBC
AhdraBC

Growth Yield and Methane Yield

mmoles l'

Std dev

p vs Parent

95.0
95.7
95.9
97.6

3.66
1.77
2.62
3.71

1
NS
NS
NS

55

Cells were adapted to methanol for 25 generations. Data were collected from ten biological
replicates (N = 10). Significance p values determined by unpaired Student's t-test, NS: not
significant, p > 0.01. Theoretical methane yield: 93.75 mmoles 1-1.

Biomass

Strain

g mol'

Std dev

p vs Parent

Example 5
60

Evaluating the Substrate Specificity of HarABC

Parent

7.295

0.7378

att::hdraBC

6.977

O.6S6S

1

NS

AhdraBC att::hdraBC

7.02O

0.7550

NS

AhdraBC

8.634

O.S642

O.OO81

65

As shown in Table 3, acetate resolves the phenotype
produced by overexpression of HarABC. Since these results
suggest that HarABC is specific for growth on methylo
trophic substrates (with chemical formula of CH3-X, where
X represents any element except carbon), experiments were
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performed to determine if HarABC uses an electron donor
produced in acetate-grown cells. To make this determina
tion, the rates of methane production on acetate Substrates
with or without methanol are measured, suggesting that
HdrABC is lacking the appropriate electron donor in
acetate-grown cells.
Example 6
Evaluating the Role of Electron Bifurcation
As shown in FIG. 5, altering HarABC enzyme activity in
the cells affects the rate of growth, the rate of methane
production, and the amount of biomass that is produced. The
amount of HarABC activity has a direct positive correlation

with the rate of methane produced from methanol (R’—1.00).
The rate of growth and methane rate have a second-order
correlation (R=0.99). The rate of growth also is correlated
to the rate of HarABC activity by a second-order relation
ship (R=0.99). Finally, the amount of biomass has a direct
negative correlation with the amount of HarABC activity
(R2–0.974).

5

18
As shown in FIG. 6, the effect of HarABC expression on
Methanosarcina is to decrease the metabolic efficiency of
the organism, i.e., more Substrate is channeled to methane
production at the expense of biomass synthesis. Metabolic
efficiency is defined by the equation:

10

kCH

15

the rate of methane production. The level of HarABC
activity and the % e have a direct negative correlation

x 100

Where k is defined as the growth rate and k is defined as
(R=0.98).
Example 7
Sequences

Mac horABC (forward)

(SEQ ID NO: 1)
atgactgacg ggctgaacaa aggtgcc.gta tittatctgcc actgcagcgg gaatattitcc
gaacatgttg at attgatgc cgtgaaaaaa acc cittaagg Cagaagggat tt cqgtttitt
gattatgagt acatgtgctic aagttcaggga caggct citta ttaaaaagaa gattgttggag
gggagcctgg acagggtggit aataggttca tgcactic cat ccaaacacgg

tactic tect tt

aaaaagtgca tacaggaaac cggtttgaac agggcagggc ttgaaattgc aaatctgagg
gaacaatgtg Cctgggtgca CCCtgaccgg accggagcta Cagaaaaagc

tottt coctic

Ctgagggc.ca aactcaaacg cctggaaaat gtagagc.ccc tggatgaaat caaagtic gat
atcgcticago aggcc Cttgt

ggaatagcag gaattacggc tgcactgaac

cittgcagata acggagtttic cactgttctt gttgagaata act caag cat aggcgggcag
atggcaaaaa tcgggaagat attitt coccg gacaa.gcttg ctgaagaatg tgcaatgtgc
t ct ct cagtic citctgatgaa tgaggttgca gcc cacccga

aaattacact

tttgacccgg

accgaagttg aaa.gc.ctgag cgggagcgca ggaaactitta cgatcaggct aaggaaaaag
ccalagatacg tcaaaga cag Ctgtacggca tgcgggaggt gCagc.cgggt ctgtc.cagtic
Caggttgaag acgagttcaa Ctgcgga cat atggacaaaa aggcaatttic tottcgcttic
tcc cagt cag tcc ccaagat c tact.gitatt gatcc.cgatt attgc ctitca gctgaatggit
gaa.gc.ctg.cg gaaaatgtgc ggatgcctgt aaaaacgaag caattgacitt tt cocagaag
gaagagat.cg ttgaacttaa cgtgggggca

ccaccgggitt tgaggagtat

gacgt.ctic cc agaaaccc.ca gtacggatac gggattitt.cg aaaacgtgct gacccagatg
gaacttgc.ca gagttcttgg catcaatggc cct acaaaag gagaact cot gagagtict ca
gattt cagca aagct tccag cgatcct acc cctgcaacct gtgattcaag gtgcgaagat
t catctgatg aatcc caagg taccgacacg c caaaaagaa tagt catgat Ccagtgttgttg
ggat Caaggg atgaaaaaga agggggaaac cgctactgtt ccagatactg Ctgcatggca
gctctgaaac atgcaa.gc.ct gattaagaala aaa catc.cgg aaacggaaat cacgatttgc
tacattgatg t cagggctitt tggitttctat gaaaattatt accgc.gcagt to aggagacic
ggagt caact ttgttgcgggg aaggcctgcc gaagttattg aaaag.ccgga talaga.gc.ctt
gttgtaagag tcgaggatac c cittgaccag aaaatgaggg aact tcc togc cg accttgtt
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ccggacagga agctct tact gtttalaga.gc tigcatggtcg ggcaggaata cc.ccggaatc
gaaa.ca.gc.ca C cagttacgt gtttgaccgg Cttgggg tag attactgcat aaacgacgag
Cagt cctgct gtacaggaat aggcc act at accgatgtct ttgaagggct cacaa.ca.gc.c
gccattgcag ccc.ggaactt to cqtcgcc agaaagtgcg ggt accc.gaa cattacctgc
citctgttcaa cct gttatgc cataaacaag gacgcatgcg

aactic Cittaa.

caccaacgat

gggg.tc.cggg aaaaagttcaa ctic catctitc cgggaaaaag gctttgatga ccttgtctat

gaaaaggact coatgaac cc cagaaccaat atctato acg Cagtic gaggt cct cotgagc
aaagttcgaaa agat.ccggga agagataaag titcgattitcC ccggcgittaa agcagcct ct
catcacgcct gcc act atta taaagttcaaa taccttgacg taatcggaaa cc.ccgaaaac
CCCC agctta tag acacgat agc.cgaagcc ticggggcat CCC ctgtgcg Ctggtacgaa
gatcgaac cc ticacctg.cgg aatgggcttt toccagotcc

acct caataa.

aag cacct ct

citcc aggtta ccaaaacaaa acttgacago citccagagag CC9gtgttgga gctaatgat c
catgtgtgcc cqaact gcca tat coagtac gaccgct acc agc.ccgittat cgaaaaagag
titcggggttg agtacgacat ggtgcacatg aac attgcc.c agttcgtagc cct ct caatg
ggagcagacic cct acaaagt atgcggitt to cagact cact cc.gtgcct ct ggaaggattt

cittgaaaaga ccggaataat ataatgtcca gtttcaaagt agaactggct

acct t t t t ta.

ttacat cqgg agtgaagaggg
Mac hors (mutated)

(SEQ ID NO:

6

LKAIESIPDR KLLLFKSCMV GOEYPGIETA TSYWFDRLGV DYCINDEOSC CTGIGHYTDV
FEGLTTAAIA, ARNFAWARKC GYPNITCLCS TCYAINKDAC ELLNTNDGWR EKWNSIFREK
GFDDLWYEKD SMNPRTNIYH AWEWLLSKWE KIREEIKFDF PGWKAASHHA CHYYKWKYLD

VIGNPENPOL IDTIAEACGA SPWRWYEDRT LTCGMGFSQL HLNKSTSLOV TKTKLDSLOR
AGVELMIHVC PNCHIOYDRY OPVIEKEFGV EYDMVHMNIA QFWALSMGAD PYKVCGFOTH
SWPLEGFLEK. TGIIk

40

are disclosed. That is, while specific reference to each
positions of matter have been described herein in conjunc various individual and collective combinations and permu
tion with a number of different aspects, the foregoing tations of these compositions and methods may not be
description of the various aspects is intended to illustrate and explicitly disclosed, each is specifically contemplated and
not limit the scope of the methods and compositions of 45 described herein. For example, if a particular composition of
matter. Other aspects, advantages, and modifications are matter or a particular method is disclosed and discussed and
within the scope of the following claims.
a number of compositions or methods are discussed, each
Disclosed are methods and compositions that can be used and every combination and permutation of the compositions
for, can be used in conjunction with, can be used in prepa and the methods are specifically contemplated unless spe
ration for, or are products of the disclosed methods and 50 cifically indicated to the contrary. Likewise, any Subset or
compositions. These and other materials are disclosed
combination of these is also specifically contemplated and
herein, and it is understood that combinations, Subsets,
interactions, groups, etc. of these methods and compositions disclosed.
It is to be understood that, while the methods and com

SEQUENCE LISTING
<16 Os NUMBER OF SEO ID NOS: 22
<21 Oc SEO ID NO 1
<211 LENGTH: 4101
<212> TYPE: DNA

ORGANISM: Methanosarcina acetivorans

<4 OOs SEQUENCE: 1

atgactgacg ggctgaacaa agctg.ccgta tittatctgcc actgcagogg gaat attt Co
galacatgttg at attgatgc cgtgaaaaaa acccttalagg cagaagggat titcggitttitt

60
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Ala Asn Luell

Arg Glu Glin

Ala

1OO

Ala Thir Glu

Trp Wall His

Ala Lell Ser Luell Luell

115

13 O

Asp Glu Ile

Gly Gly Gly

145

Ile Ala

Gly

150

Asp

Asn

Gly

Gly Gly

Gly

Arg

Wall

Ile

Gly Lys

Ala Met

17s

Ile Phe Ser Pro

Cys

Ser Luell Ser Pro Lell Met Asn Glu

Ile Thir Luell Luell Thir

Ser Ala
23 O

Gly

Lys Asp

Ser

Ala Ile Ser Lell

Asn Phe Thir Ile
235

Asp

Pro

Asp

Asp Glu Phe

Asp Ala Cys

Gly His

Ser Glin Ser Wall Pro
285

Lieu Glin Lieu Asn

Gly

3.25
Ser Glin

34 O

Gly

Asp Phe

Ala Wall Wall Wall Ala Thir

Gly

Lys

335

Pro Glin

Tyr Gly Tyr Gly Ile
35. O

Arg Wall

Asp

385

Asp Glu

Ile Glin

Glu Luell Luell

Ser

Asp Phe

Ser

Asp

Ser

Arg

Glu

Wall

Pro Thir Pro Ala Thir
390
Ser Glin
4 OS

Gly

Gly

Arg Asp Glu

Ser

Arg

Thir

395

Asp Thir

Arg Ile Wall

Pro

Glu

Gly Gly

Lys His Ala

465

Met

Asn
43 O

Arg

Ser Luell Ile

445

45.5

Arg Ala Phe Gly Phe Tyr Glu

Asp

415

His Pro Glu Thir Glu Ile Thir Ile Cys

450

Ile

Asp Wall

460
Asn

Tyr

Arg Ala Wall Glin Glu Thir

470

Wall Asn Phe Wall

Arg Gly Arg

485

Asp

Ile

4 OO

41O

Met Ala Ala Luell
44 O

435

Gly

Gly

Arg Wall

425

Lys

Luell

365

375

Ala Ser Ser

Ser

Gly
Lys

360

Gly

Asp

Ser Glin

Phe Glu Asn Wall Lell Thir Glin Met Glu Luell Ala

Pro Thir

Met

Glu Ala

345

37 O

Arg

Ile

330

355

Ser
255

3 OO

Glu Glu Ile Wall Glu Lell Asn Wall

Tyr Asp Wall

Lys

27 O

Asn Glu Ala Ile
315

310

Phe Glu Glu

Arg

24 O

ASn

295

Ala

Lell

265

Arg Phe

Cys

29 O

3. OS

Arg

Gly Arg

Thir Ala

28O

Ser Ser

Arg Thir Glu Wall Glu

250

Pro Wall Glin Wall Glu
26 O

Gly

Asp

19 O

2OO

245

Asn

160

215

Ser Luell Ser
225

Lys

Ile Thir Ala Ala Luell Asn

185

21 O

Ile

Asp Ile Ala Glin Glin

17O

Wall Ala Ala His Pro

Wall

Luell

Wall Ser Thir Wall Luell Wall Glu Asn Asn Ser Ser

Glin Met Ala

Lell Ala Glu Glu
195

Lys Arg

155

18O

Pro

Wall

Lell
125

14 O

1.65

Ile

Arg Ala Lys

135

Ala Luell Wall Ile

Asp Arg Thir Gly
11 O

12 O

Glu Asn Wall Glu Pro Lell

Lell Ala

Pro

105

Ser Luell Wall Wall
SOO

Pro Ala Glu Wall Ile Glu Lys Pro
490
495

Arg Wall Glu Asp Thir
505

Lell

Asp Glin
51O

Met
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Arg Glu

Luell Pro Ala
515

Ser Pro
53 O

Gly

Glu Ser

Gly

Thir

Asp

Arg

Lell Wall Wall Luell Ser Ala Ala Met Wall Pro
525

Ile Ala Ser Wall Luell Asn Lell Ser Glin
535

Phe Ile

5.45

Lys Glu Arg His

Ser

550

Ser Ser Luell

Lys

565

Thir Ala Glin Ser Pro

st O

sts

585
Ser Pro

Luell Ala Ala Wall
59 O

Wall Luell

Asp

Gly

Glu

595

610
Pro Phe
625

Cys Thir Arg

Asp Ala

Lell Ser Wall Asn Glu Ser Gly
630
635

Thir

Gly

Gly

Ala Wall Glin Ile Ala

Gly

Phe Thir

Gly

Gly

Lell

Gly Asp

Asp
Glu

655
Luell Glin Lell

665

Wall Lell Glu Glu

Luell

64 O

Lys Ala Glu
67 O

Wall Luell

Gly

675

Tyr

Luell

650

660

Gly

Asn Glu Ile Ala
605

Arg Wall Wall

Cys Thir

645

Met Glu

Arg Ala

615

Pro Luell Ile

Gly

Asp
560

Gly

Asp Wall Thir Asp Thir Ile Ala Glin Ala Gly

Thir Ile Asn Glin Lell Lell

Pro Wall

Lell

555

Asp Gly Ile Phe Wall

Arg Ala Phe Ile Thir Asp

Asp

54 O

Phe Wall Asn Ser
685

Ile Ala Ser Lell Thir

Cys Asp

69 O.

695

Pro Ser Asn Wall

Lys

Asn Ile

Lieu Ile

Gly

Asn Ser Wall Luell Thir
7 OO

Wall Pro Thr

Gly

Luell Wall Wall

7 Os

Asp Arg Asp

Luell Wall Lell His Ala Phe Arg His
72
73 O

Lell Phe Wall Glu
740

Asp

Pro Pro

Asp

Asn Pro
74.

Gly

Asn

Arg Ile

Phe

770

Gly

Ala

Luell Ala

Gly

73

7 O

Glu Glu Luell

Gly

765

Tyr Wall

775

Pro Asn Thir

78O

Thir Phe Thir Ser Luell Ala

78s

Ala Ser Ser Wall

Arg Ala Glu Wall Ile

Pro Luell Thir Wall Ser His Phe Glu Glu Luell
760
Ser

Gly

79 O

Arg Glu Gly Glu
79.

Met Ile
8OO

Arg
SEQ ID NO 3
LENGTH: 314
TYPE : PRT

ORGANISM: Methanosarcina acetivorans
< 4 OOs

SEQUENCE: 3

Lell
1.

Lys Ala Ile Glu

Ser

Cys

Ser Ile Pro

Met Wall

Wall Phe

Gly

Asp Arg

1O

Glin Glu

Lell

Gly

35
Ser

Cys

Pro
25

Wall

Gly

Lell Lell Luell Phe
15

Ile Glu Thir Ala Thir Ser
3O

Asp

Ile Asn

4O

Thir

Gly

Ile

SO

Gly His
55

Thir Thir Ala Ala Ile Ala Ala
65

Asp Arg

5

70

Asp Glu Glin

45

Thir

Asp Wall Phe Glu Gly
6O

Arg

Asn Phe Ala Wall Ala
7s

Arg

Luell
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Gly Tyr

Pro Asn Ile Thir
85

Asp Ala Cys Glu
1OO

Lell Lell Asn Thir Asn
105

Wall Asn Ser Ile Phe

Glu

115

Asp

Ser Met Asn Pro

11 O

Lys Gly Phe Asp Asp

Arg Thir

Wall Glu

Ile

Arg Glu Glu Ile

Asp Wall Ile Gly

Gly

17s

Asn Pro Glu ASn Pro Glin Luell Ile
185
19 O

Ala Ser Pro Wall

Arg Trp

Gly

Luell Thir

Met
215

Gly

Ser Thir Ser Luell Glin Wall Thir
225
23 O

Asp

Phe Ser Glin Lell His Luell Asn

Thir

Wall Glu Lell Met Ile His Met
245

Asp Arg Tyr Glin
26 O

Asp

Glu

Asp

2O5

21 O

Gly

Lys Wall

His

195

Ala

Asp Phe
160

17O

18O

Arg Thir

Phe

155

Ala Ala Ser His His Ala

Thir Ile Ala Glu Ala

Glu

14 O

1.65
Luell

Lell Wall
125

His Ala Wall Glu Wall

Asn Ile

150

Wall

Asn

95

Asp Gly Wall Arg Glu

135

Lell Luell Ser
145

Gly

Cys Tyr Ala Ile

12 O

13 O

Pro

Ser Thir
90

Luell

Luell
235

Cys

Asp

Ser Luell Glin

24 O

His Ile Glin

Pro Asn

250
Pro Wall Ile Glu
265

Arg

255

Glu Phe

Gly

Wall Glu
27 O

Met Wall His Met Asn Ile Ala Gln Phe Wall Ala Lieu Ser Met

Gly

285

Ala

Asp

Wall

Pro

29 O

Glu

Gly

Cys Gly Phe Glin Thir His
295

Phe Luell Glu

3. OS

Ser Wall Pro Luell

3 OO

Lys Thir Gly Ile Ile
310

<210s, SEQ ID NO 4
&211s LENGTH: 247
212. TYPE : PRT

<213> ORGANISM: Methanosarcina acetivorans

<4 OOs, SEQUENCE: 4.
Met Ile Pro
1.
Pro Glu

Tyr Wall Lys

Cys Lys Thir

Pro Glu Ser Luell
35

Ala Ser

Tyr Wall

Gly

Lell Ala Glu Thir Ala
25
Lell

Asp Arg

Lys Lys

Arg Phe Thir Asp Tyr

Wall Lell Glu Asn

Arg Thir

Ala

Thir

45

55

65

Ser Ile
3O

Gly

Ile Glin

4O

Pro Ala Ala

Wall

Asp Thir

Asn Glu

15

SO

Ile

Met Met Pro

5

Asp Arg

Ser Pro
6O

Arg Glin Ile

Ser Wall Lell Glu Ser Glu Met

70

Trp

Phe

Ser

Tyr

Ser

85

Cys

ASn Lell

Asn Asn Ser Pro Wall Thir Ile Wall Glin Wall Luell
1OO
105
Asn Glu

Gly

Ile

Arg Wall Glu Lys

115

Glu His Luell
13 O

Luell Ala

Arg Glin

Glu Asn

Pro
95

Gly
135

Ala Ser

Arg

Met Ala Ile
11 O

Tyr Phe

Lell Glu Ile
125

Gly

Wall Pro

Gly

Ile

12 O

Gly

Arg

90

14 O

Ala

Gly
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Catgtgtgcc caactgc.ca tat coagtac gaccgct acc agc.ccgttat caaaaagag

3900

titcggggttg agtacgacat ggtgcacatgaac attgc.cc agttcgtagc cct ct caatg

396 O

ggagcagacic cct acaaagt atgcggtttc Cagactic act C cqtgcctct ggaaggattt

4 O2O

cittgaaaaga ccggaataat ataatgtcca gtttcaaagt agaactggct accttttitta

4 O8O

ttacat cqgg agtgaagaggg

41 O1

<210s, SEQ ID NO 6
&211s LENGTH: 314
212. TYPE: PRT

<213> ORGANISM: Methanosarcina acetivorans
22 Os. FEATURE:
223 OTHER INFORMATION: multant

<4 OOs, SEQUENCE: 6

Lieu Lys Ala Ile Glu Ser Ile Pro Asp Arg Llys Lieu Lleu Lieu. Phe Lys
1.

5

1O

15

Ser Cys Met Val Gly Glin Glu Tyr Pro Gly Ile Glu Thir Ala Thir Ser
2O

25

3O

Tyr Val Phe Asp Arg Lieu. Gly Val Asp Tyr Cys Ile Asn Asp Glu Glin
35

4O

45

Ser Cys Cys Thr Gly Ile Gly His Tyr Thr Asp Val Phe Glu Gly Lieu.
SO

55

6O

Thir Thr Ala Ala Ile Ala Ala Arg Asn. Phe Ala Val Ala Arg Lys Cys
65

70

7s

8O

Gly Tyr Pro Asn Ile Thr Cys Lieu. Cys Ser Thr Cys Tyr Ala Ile Asn
85

90

95

Lys Asp Ala Cys Glu Lieu. Lieu. Asn. Thir Asn Asp Gly Val Arg Glu Lys
1OO

105

11 O

Val Asn. Ser Ile Phe Arg Glu Lys Gly Phe Asp Asp Lieu Val Tyr Glu
115

12 O

125

Lys Asp Ser Met Asn Pro Arg Thr Asn. Ile Tyr His Ala Val Glu Val
13 O

135

14 O

Lieu. Lieu. Ser Llys Val Glu Lys Ile Arg Glu Glu Ile Llys Phe Asp Phe
145

150

155

160

Pro Gly Val Lys Ala Ala Ser His His Ala Cys His Tyr Tyr Llys Val
1.65

17O

17s

Llys Tyr Lieu. Asp Val Ile Gly Asn Pro Glu Asn. Pro Gln Lieu. Ile Asp
18O

185

19 O

Thir Ile Ala Glu Ala Cys Gly Ala Ser Pro Val Arg Trp Tyr Glu Asp
195

2OO

2O5

Arg Thr Lieu. Thr Cys Gly Met Gly Phe Ser Gln Lieu. His Lieu. Asn Lys
21 O

215

22O

Ser Thir Ser Lieu. Glin Val Thir Lys Thir Lys Lieu. Asp Ser Lieu. Glin Arg
225

23 O

235

24 O

Ala Gly Val Glu Lieu Met Ile His Val Cys Pro Asn Cys His Ile Glin
245

250

255

Tyr Asp Arg Tyr Glin Pro Val Ile Glu Lys Glu Phe Gly Val Glu Tyr
26 O

265

27 O

Asp Met Val His Met Asn Ile Ala Glin Phe Val Ala Leu Ser Met Gly
27s

28O

285

Ala Asp Pro Tyr Lys Val Cys Gly Phe Glin Thr His Ser Val Pro Leu
29 O

295

Glu Gly Phe Leu Glu Lys Thr Gly Ile Ile
3. OS

310

3 OO

US 9,598,678 B2
44

43
- Continued
<210s, SEQ ID NO 7
&211s LENGTH: 33
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: synthetic oligonucleotide
<4 OO > SEQUENCE: 7

ggat.cccata tactgacgg gctgaacaaa gCt

33

<210s, SEQ ID NO 8
&211s LENGTH: 46
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: synthetic oligonucleotide
<4 OOs, SEQUENCE: 8

ggat.ccc.cct citt cactic cc gatgtaataa aaaaggtagc cagttc

46

<210s, SEQ ID NO 9
&211s LENGTH: 43
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: synthetic oligonucleotide
<4 OOs, SEQUENCE: 9

gagaaattgc ctittttgtcc atgtgtc.cgc agttgaactic gtc
<210

43

SEQ ID NO 10

&211s LENGTH: 43
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: synthetic oligonucleotide
<4 OOs, SEQUENCE: 10

gacgagttca actg.cggaca catggacalaa aaggcaattt Ctc

43

<210s, SEQ ID NO 11
&211s LENGTH: 42
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: synthetic oligonucleotide
<4 OOs, SEQUENCE: 11

c ctitttgttgttcggaacgta togcttttittgaaatagatcc gg

42

<210s, SEQ ID NO 12
&211s LENGTH: 42
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: synthetic oligonucleotide
<4 OOs, SEQUENCE: 12

ccggat citat ttcaaaaaag catacgttcc gaacacaaaa go
<210s, SEQ ID NO 13
&211s LENGTH: 39
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: synthetic oligonucleotide

42
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<4 OOs, SEQUENCE: 13

ggcatcatct ttacataggg tat catctta t catctotc

39

<210s, SEQ ID NO 14
&211s LENGTH: 39
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: synthetic oligonucleotide
<4 OOs, SEQUENCE: 14

gagagatgat aagatgatac Cctatgtaaa gatgatgcc

39

<210s, SEQ ID NO 15
&211s LENGTH: 43
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: synthetic oligonucleotide
<4 OOs, SEQUENCE: 15

gggitat cqta titcgtttaca tagggcatca totttacata togg

43

<210s, SEQ ID NO 16
&211s LENGTH: 43
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: synthetic oligonucleotide
<4 OOs, SEQUENCE: 16

c catatgtaa agatgatgcc ctatotaaac gaatacgata ccc

43

<210s, SEQ ID NO 17
&211s LENGTH: 42
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: synthetic oligonucleotide
<4 OOs, SEQUENCE: 17

gatatggcag titcgggcaca ttggat cat tagct coaca CC

42

<210s, SEQ ID NO 18
&211s LENGTH: 42
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: synthetic oligonucleotide
<4 OOs, SEQUENCE: 18

ggtgtggagc taatgatcca catgtgc.ccg aactgccata t c
<210s, SEQ ID NO 19
&211s LENGTH: 2O
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: synthetic oligonucleotide
<4 OOs, SEQUENCE: 19

tactggggitt totgggagac

42
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SEQ ID NO 2 O
LENGTH: 22
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: synthetic oligonucleotide
<4 OOs, SEQUENCE: 2O

atggtcttgc tict cagcgat ga

22

SEQ ID NO 21
LENGTH: 26
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: synthetic oligonucleotide
<4 OOs, SEQUENCE: 21

aggtgttggt atgaaaatca gcaagg

26

SEQ ID NO 22
LENGTH: 30
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: synthetic oligonucleotide
<4 OOs, SEQUENCE: 22

atcagtgata gagattt cat tgaatagt

3O

What is claimed is:

1. A mutant heterodisulfide reductase-like protein subunit
B (HdrB) polypeptide, wherein the mutant HarB polypep
tide comprises an amino acid sequence with at least 95%
sequence identity to the amino acid sequence of SEQ ID
NO: 3, wherein methionine at the amino acid corresponding
to position 249 of SEQ ID NO: 3 is substituted with valine
in the mutant HarB polypeptide, and wherein when the
mutant HarB polypeptide is combined with a heterodisulfide
reductase-like protein subunit A (HdrA) polypeptide and a
heterodisulfide reductase-like protein subunit C (HdrC)
polypeptide forms an HarABC enzyme that has heterodis
ulfide reductase activity.
2. The mutant HarB polypeptide of claim 1, wherein the
mutant HarB polypeptide comprises the amino acid
sequence of SEQ ID NO:6.
3. A nucleic acid molecule comprising a polynucleotide
encoding the mutant HarB polypeptide of claim 1.

35

of claim 3.

40
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4. The nucleic acid molecule of claim 3, wherein the

polynucleotide comprises the nucleotide sequence of SEQ
ID NO: 5.

5. The nucleic acid molecule of claim 3, wherein the

mutant HarB polypeptide comprises the amino acid
sequence of SEQ ID NO: 6.
6. The nucleic acid molecule of claim 1, further compris
ing a polynucleotide encoding a heterodisulfide reductase

like protein subunit A (HdrA) polypeptide and a polynucle
otide encoding a heterodisulfide reductase-like protein
subunit C (HdrC) polypeptide.
7. A microorganism comprising the nucleic acid molecule
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8. The microorganism of claim 7, wherein the microor
ganism is a methanogen.
9. The microorganism of claim 8, wherein the microor
ganism is Methanosarcina acetivorans.
10. The microorganism of claim 7, wherein the nucleic
acid molecule is expressed in the microorganism via an
expression vector.
11. A microorganism comprising the nucleic acid mol
ecule of claim 6.

12. The microorganism of claim 11, wherein the micro
organism is a methanogen.
13. The microorganism of claim 12, wherein the micro
organism is Methanosarcina acetivorans.
14. The microorganism of claim 11, wherein the nucleic
acid molecule is expressed in the microorganism via an
expression vector.
15. A method of producing methane, comprising culturing
the microorganism of claim 11 under appropriate conditions
to express the HarA polypeptide, the mutant HarB polypep
tide, and the HarC polypeptide and produce methane.
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